PMID- 26859851
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1424-8638 (Electronic)
IS  - 1424-862X (Linking)
VI  - 24
IP  - 1
DP  - 2016
TI  - Role of Serum Brain Derived Neurotrophic Factor and Central N-Acetylaspartate for 
      Clinical Response under Antidepressive Pharmacotherapy.
PG  - 1-14
LID - 10.1159/000442607 [doi]
AB  - BACKGROUND: The predictive therapeutic value of brain derived neurotrophic factor 
      (BDNF) and its changes associated with the use of specific antidepressants are 
      still unclear. In this study, we examined BDNF as a peripheral and NAA as a 
      central biomarker over the time course of antidepressant treatment to specify 
      both of their roles in the response to the medication and clinical outcome. 
      METHODS: We examined serum BDNF (ELISA kit) in a sample of 76 (47 female and 29 
      male) depressed patients in a naturalistic setting. BDNF was assessed before 
      medication and subsequently after two, four and six weeks of antidepressant 
      treatment. Additionally, in fifteen patients, N-acetylaspartate (NAA) was 
      measured in the anterior cingulate cortex (ACC) with magnetic resonance 
      spectroscopy (MRS). Over a time course of six weeks BDNF and NAA were also 
      examined in a group of 41 healthy controls. RESULTS: We found significant lower 
      serum BDNF concentrations in depressed patients compared to the sample of healthy 
      volunteers before and after medication. BDNF and clinical symptoms decreased 
      significantly in the patients over the time course of antidepressant treatment. 
      Serum BDNF levels at baseline predicted the symptom outcome after eight weeks. 
      Specifically, responders and remitters had lower serum BDNF at baseline than the 
      nonresponders and nonremitters. NAA was slightly decreased but not significantly 
      lower in depressed patients when compared with healthy controls. During treatment 
      period, NAA showed a tendency to increase. LIMITATIONS: A relative high drop-out 
      rate and possibly, a suboptimal observation period for BDNF. CONCLUSION: Our data 
      confirm serum BDNF as a biomarker of depression with a possible role in response 
      prediction. However, our findings argue against serum BDNF increase being a 
      prerequisite to depressive symptom reduction.
CI  - (c) 2016 The Author(s) Published by S. Karger AG, Basel.
FAU - Nase, Sarah
AU  - Nase S
AD  - Department of Psychiatry and Psychotherapy, Charite, University Medicine Berlin, 
      Campus Mitte, Berlin, Germany.
FAU - Kohler, Stephan
AU  - Kohler S
FAU - Jennebach, Jacqueline
AU  - Jennebach J
FAU - Eckert, Anne
AU  - Eckert A
FAU - Schweinfurth, Nina
AU  - Schweinfurth N
FAU - Gallinat, Jurgen
AU  - Gallinat J
FAU - Lang, Undine E
AU  - Lang UE
FAU - Kuhn, Simone
AU  - Kuhn S
LA  - eng
PT  - Journal Article
DEP - 20160201
PL  - Switzerland
TA  - Neurosignals
JT  - Neuro-Signals
JID - 101134359
OTO - NOTNLM
OT  - Antidepressant therapy
OT  - Brain derived neurotrophic factor
OT  - Depression
OT  - N-acetylaspartate
OT  - Neuroimaging
OT  - Neurotrophins
EDAT- 2016/02/10 06:00
MHDA- 2016/02/10 06:01
CRDT- 2016/02/10 06:00
PHST- 2015/12/18 00:00 [accepted]
PHST- 2016/02/10 06:00 [pubmed]
PHST- 2016/02/10 06:01 [medline]
PHST- 2016/02/10 06:00 [entrez]
AID - 000442607 [pii]
AID - 10.1159/000442607 [doi]
PST - ppublish
SO  - Neurosignals. 2016;24(1):1-14. doi: 10.1159/000442607. Epub 2016 Feb 1.